Literature DB >> 25684797

Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma.

Samantha Bryant1, Dominic A Solimando1, J Aubrey Waddell1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2015        PMID： 25684797      PMCID： PMC4321425          DOI： 10.1310/hpj5001-25

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  14 in total

1.  Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.

Authors:  Fortunato Morabito; Massimo Gentile; Carla Mazzone; Davide Rossi; Francesco Di Raimondo; Sara Bringhen; Roberto Ria; Massimo Offidani; Francesca Patriarca; Chiara Nozzoli; Maria Teresa Petrucci; Giulia Benevolo; Iolanda Vincelli; Tommasina Guglielmelli; Mariella Grasso; Roberto Marasca; Luca Baldini; Vittorio Montefusco; Pellegrino Musto; Nicola Cascavilla; Ignazio Majolino; Caterina Musolino; Michele Cavo; Mario Boccadoro; Antonio Palumbo
Journal:  Blood       Date:  2011-09-27       Impact factor: 22.113

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 3.  Proposal for classifying the acute emetogenicity of cancer chemotherapy.

Authors:  P J Hesketh; M G Kris; S M Grunberg; T Beck; J D Hainsworth; G Harker; M S Aapro; D Gandara; C M Lindley
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

Review 4.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

5.  Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

Authors:  María-Victoria Mateos; José-M Hernández; Miguel-T Hernández; Norma-C Gutiérrez; Luis Palomera; Marta Fuertes; Joaquín Díaz-Mediavilla; Juan-J Lahuerta; Javier de la Rubia; María-José Terol; Ana Sureda; Joan Bargay; Paz Ribas; Felipe de Arriba; Adrian Alegre; Albert Oriol; Dolores Carrera; José García-Laraña; Ramón García-Sanz; Joan Bladé; Felipe Prósper; Gemma Mateo; Dixie-Lee Esseltine; Helgi van de Velde; Jesús-F San Miguel
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

6.  Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

Authors:  Patricia M LoRusso; Karthik Venkatakrishnan; Ramesh K Ramanathan; John Sarantopoulos; Daniel Mulkerin; Stephen I Shibata; Anne Hamilton; Afshin Dowlati; Sridhar Mani; Michelle A Rudek; Chris H Takimoto; Rachel Neuwirth; Dixie-Lee Esseltine; Percy Ivy
Journal:  Clin Cancer Res       Date:  2012-03-06       Impact factor: 12.531

7.  Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

Authors:  María-Victoria Mateos; Albert Oriol; Joaquín Martínez-López; Norma Gutiérrez; Ana-Isabel Teruel; Raquel de Paz; José García-Laraña; Enrique Bengoechea; Alejandro Martín; Joaquín Díaz Mediavilla; Luis Palomera; Felipe de Arriba; Yolanda González; Jose-Mariano Hernández; Ana Sureda; José-Luis Bello; Joan Bargay; Francisco-Javier Peñalver; José-María Ribera; María-Luisa Martín-Mateos; Ramón García-Sanz; María-Teresa Cibeira; María-Luisa Martín Ramos; María-Belén Vidriales; Bruno Paiva; María-Angeles Montalbán; Juan-José Lahuerta; Joan Bladé; Jesús-Fernando San Miguel
Journal:  Lancet Oncol       Date:  2010-08-23       Impact factor: 41.316

8.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau
Journal:  Lancet Oncol       Date:  2011-04-18       Impact factor: 41.316

9.  Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.

Authors:  Youngil Koh; So Young Lee; Inho Kim; Ji-Hyun Kwon; Sung-Soo Yoon; Seonyang Park; Mi Hye Chung; Sung Yun Suh; Kwi Suk Kim; Hyang Sook Kim
Journal:  Cancer Chemother Pharmacol       Date:  2014-08-06       Impact factor: 3.333

10.  VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.

Authors:  Meletios A Dimopoulos; Paul G Richardson; Rudolf Schlag; Nuriet K Khuageva; Ofer Shpilberg; Efstathios Kastritis; Martin Kropff; Maria T Petrucci; Michel Delforge; Julia Alexeeva; Rik Schots; Tamás Masszi; Maria-Victoria Mateos; William Deraedt; Kevin Liu; Andrew Cakana; Helgi van de Velde; Jesús F San Miguel
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.